AKTUELLE STUDIEN | CURRENT TRIALS

Ongoing Clinical Trials in Dermatology and Venereology in Austria

Sponsor | Principal investigator | Contact email | Patient recruitment until

Graz

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)

Immunocore | Rainer Hofmann-Wellenhof | studien.derma-onko@uniklinikum.kages.at | December 2027

A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants with Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Immunocore | Rainer Hofmann-Wellenhof | studien.derma-onko@uniklinikum.kages.at | December 2027

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema (RAPIDe-2)

Pharvaris | Birger Kränke | clemens.schoeffl@medunigraz.at | June 2027

Phase II Study of Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in Patients with Locally Advanced/Metastatic Squamous Cell Carcinoma of the Skin

Universitätsklinik für Dermatologie und Allergologie Salzburg | Paracelsus Medizinische Privatuniversität | Rainer Hofmann-Wellenhof | studien.derma-onko@uniklinikum.kages.at | December 2027

A Phase 2 and Phase 3 Peri-Operative Trial of Fianlimab (REGN3767, ANTI-LAG-3) + Cemiplimab versus Anti-PD1 Alone Pembrolizumab in Patients with Resectable Stage III and IV Melanoma

Regeneron Pharmaceuticals, Inc. | Teresa Maria Kränke | studien.derma-onko@uniklinikum.kages.at | December 2027

A Multi-Centre, Randomised, Placebo-Controlled, Double-Blind, Parallel-Group Trial to Evaluate Safety and Efficacy of Spesolimab (BI 655130) i.v. in Adult Patients with Ulcerative Pyoderma Gangrenosum (PG) Who Require Systemic Therapy

Boehringer-Ingelheim | Peter Wolf | peter.wolf@medunigraz.at | December 2027

A Phase 3, Open-Label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children from 2 to Less than 12 Years of Age with Moderate to Severe Atopic Dermatitis

Abbvie | Barbara Binder | martina.praszl-posch@medunigraz.at | December 2026

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory and/or Intolerant to Antimalarial Therapy

AstraZeneca | Wolfgang Salmhofer | martina.praszl-posch@medunigraz.at | December 2026

A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma

Eikon Therapeutics | Teresa Maria Kränke | studien.derma-onko@uniklinikum.kages.at | n.a.

Innsbruck

Erythropoetische Protoporphyrie (EPP)-SCENESSE Studie CUV-PASS-001 Unbedenklichkeitsstudie | Krankheitsregister-Studie nach der Zulassung zur Gewinnung von Daten zur Langzeitsicherheit und klinischen Wirksamkeit von SCENESSE (Afamelanotid 16 mg) bei Patienten mit erythropoetischer Protoporphyrie

Clinuvel | Robert Gruber | robert.gruber@tirol-kliniken.at | n.a.

Plattenepithelkarzinomstudie – NIVOSQUACS Studie NIVOSQUACS-CA209-587 Eine Phase-II-Studie zu Nivolumab und Relatlimab bei Patienten mit vorbehandeltem, lokal fortgeschrittenem /metastasierendem Plattenepithelkarzinom der Haut

PMU Salzburg | Van Anh Ngyuen | van.nguyen@i-med.ac.at | n.a.

Melanom-Phase-III-Studie von REGENERON R3767-ONC-2011 mit Fianlimab REGN3767, Anti-LAG-3-Antikörper plus Cemiplimab versus Pembrolizumab bei Patienten mit zuvor unbehandeltem irresektablem lokal fortgeschrittenem oder metastasiertem Melanom

Regeneron Pharmaceuticals, Inc. | Van Anh Nguyen | van.nguyen@i-med.ac.at | n.a.

Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Anifrolumab bei Erwachsenen mit chronisch und/oder subakut kutanem Lupus erythematodes, die nicht auf eine Malariatherapie ansprechen oder diese nicht vertragen

AstraZeneca | Barbara Böckle | barbara.boeckle@i-med.ac.at | n.a.

Studie zur Beurteilung der Wirksamkeit der Behandlung mit Anifrolumab im medizinischen Alltag – Multinationale Beobachtungsstudie nach Markteinführung zur Wirksamkeit bei SLE-Patienten, die Anifrolumab im Rahmen der klinischen Standardversorgung erhalten

AstraZeneca | Barbara Böckle | barbara.boeckle@i-med.ac.at | n.a.

Prospektive Validierung eines neuen Biochips zur Diagnostik blasenbildender Autoimmunerkrankungen

Med Uni Innsbruck | Barbara Böckle | barbara.boeckle@i-med.ac.at | n.a.

Hormon-Spiegel und Allergiemarkermessung bei Patienten mit (V.a.) Allergie/allergischer Diathese Kurztitel: „Diagnose- und Prognoseparameter bei allergologischen Erkrankungen“

Med Uni Innsbruck | Paul Bellmann, Moosbrugger-Martinz | paul.bellmann@i-med.ac.at, verena.martinz@i-med.ac.at | n.a.

Social Derma: Eine Fragebogenstudie zur Evaluierung des Einflusses von Sozialen Medien auf Hautgesundheit, Hautvorsorge und Hautpflege

Med Uni Innsbruck | Maximilian Lammer, Matthias Schmuth | maximilian.lammer@i-med.at , matthias.schmuth@i-med.ac.at | n.a.

„Real-world“ klinische Endpunkte bei Patienten mit Merkelzellkarzinom, die in Österreich mit Avelumab behandelt wurden: eine retrospektive Multicenter-Studie

Med Uni Innsbruck | Maximilian Lammer, Van Anh Nguyen | maximilian.lammer@i-med.ac.at, van.nguyen@i-med.ac.at | n.a.

Eine doppelblinde, randomisierte, placebokontrollierte Studie der Phase III zur Wirksamkeit und Sicherheit von Povorcitinib (INCB054707) bei Teilnehmern mit mittelschwerer bis schwerer Hidradenitis suppurativa (Akne inversa)

Regeneron | Matthias Schmuth | matthias.schmuth@i-med.ac.at

Eine randomisierte, doppelblinde Phase-III-Studie zur Wirksamkeit und Sicherheit der Ruxolitinib-Creme bei Kindern (6 bis < 12 Jahre) mit nichtsegmentaler Vitiligo

INCYTE Corporation | Matthias Schmuth | matthias.schmuth@i-med.ac.at

Eine europäische, multizentrische, prospektive klinische Phase-IV-Beobachtungsstudie zur Bewertung des Einflusses von Lebrikizumab auf das gesundheitsbezogene Wohlbefinden und die Kontrolle von Hautmanifestationen bei Patienten mit mittelschwerer bis schwerer Neurodermitis (ADTrust)

Almirall | Robert Gruber | robert.gruber@tirol-kliniken.at

REAL-LAG – Real-World Effectiveness and Safety of Nivolumab/Relatlimab in Patients with Advanced Melanoma

Medizinische Universität Innsbruck | Marina Wanner, Van Anh Nguyen | marina.wanner@i-med.ac.at | Oktober 2026

Sun Exposure, Photoprotection Behaviors, and UV-Related Disease Burden in Patients with Cutaneous and Systemic Lupus Erythematosus: A Cross-Sectional Questionnaire Study

Medizinische Universität Innsbruck | Marina Wanner, Barbara Böckle | marina.wanner@i-med.ac.at

Salzburg

A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-positive Participants with Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Immunocore | Peter Kölblinger | p.koelblinger@salk.at | n.a.

European, Multicenter, Prospective Observational Phase IV Clinical Study to Assess the Impact of Lebrikizumab on Health-related Well-being and Control of Skin Manifestations in Patients with Moderate-to-Severe Atopic Dermatitis (ADTrust)

Almirall | Damian Meyersburg | d.meyersburg@salk.at | n.a.

EPIK-P4: A Phase II Single Arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients with PIK3CA-Related Overgrowth Spectrum (PROS)

Novartis | Christine Wagger | c.wagger@salk.at | n.a.

Investigator-sponsored Trial (BMS) NIVOSQUACS (CA209-587) (akademische Eigenstudie): Phase II Study of Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in Patients with Locally Advanced/ Metastatic Squamous Cell Carcinoma of the Skin

PMU Salzburg | Martin Laimer | m.laimer@salk.at | Dezember 2026

A Multi-centre, Randomised, Placebo-controlled, Double-blind, Parallel Group Trial to Evaluate Safety and Efficacy of Spesolimab (BI 655130) i.v. in Adult Patients with Ulcerative Pyoderma Gangrenosum Who Require Systemic Therapy (1368-0140)

Boehringer-Ingelheim | Martin Laimer | m.laimer@salk.at | n.a.

Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children from 2 to Less than 12 Years of Age with Moderate to Severe Atopic Dermatitis (Startup)

Abbvie | Christine Wagger | c.wagger@salk.at | Dezember 2026

Wien

A Two-Part, Phase 3 Trial Evaluating the Efficacy and Safety of Tildrakizumab 200 mg in Adults with Moderate-to-Severe Plaque Psoriasis and Short Disease Duration (≤ 2 years): Open-Label Treatment Followed by a Randomised, Double-Blind, Dose-Spacing Maintenance Period

Almirall | Constanze Jonak | constanze.jonak@meduniwien.ac.at | Patient Recruitment beginning Februar 2027

Development of the European Organisation for Research and Treatment of Cancer (EORTC)/Cutaneous Lymphoma Task Force (CLTF) questionnaire to assess HRQoL in cutaneous lymphoma – Phase 1b and 2

EORTC | Kevin Molloy, Constanze Jonak | constanze.jonak@meduniwien.ac.a | Patient Recruitment beginning Dezember 2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants with Prurigo Nodularis

ICON plc | Paul Sator | Paul.Sator@gesundheitsverbund.at | June 2027

Rollover Study for Participants Who Have Completed a Previous Study with Anifrolumab (Saphnelo®) and Clinically Benefited from Continued Treatment

AstraZeneca | Christian Posch | christian.posch@gesundheitsverbund.at

---

Hidradenitis Suppurativa Patients Treated with Bimekizumab: A Real-Life Long-Term Prospective Observation of Health Outcomes (Hi-LiGHT)

UCB Biopharma SRL | Christian Posch | christian.posch@gesundheitsverbund.at

---

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Multinational Trial to Evaluate the Safety and Efficacy of a 4-Week Treatment with AKR101 Gel in Patients with Venous Leg Ulcers

Akribes Biomedical | Christian Posch | christian.posch@gesundheitsverbund.at | n.a.

A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants with Severe Chronic Pruritus of Unknown Origin (CPUO)

Novartis Pharmaceuticals | Christian Posch | christian.posch@gesundheitsverbund.at

---

A Prospective, Observational Study to Evaluate the Effectiveness of Upadacitinib and Biologics on the Achievement of Minimal Disease Activity in Patients with Moderate-to-Severe Atopic Dermatitis (RAMpUp)

AbbVie | Christian Posch | christian.posch@gesundheitsverbund.at | March 2028

A Multicentre, Prospective Observational Phase IV Clinical Study to Assess the Impact of Lebrikizumab on Burdensome Body Areas in Patients with Moderate-to-Severe Atopic Dermatitis – the ADimpact Study

Almirall | Christian Posch | christian.posch@gesundheitsverbund.at | n.a

---

The deadline of notification for the next issue of SKIN is December 15, 2026.
Please email your study to: editors@skinonline.at

Der Meldeschluss für die nächste Ausgabe von SKIN ist der 15. Dezember 2026.
Bitte senden Sie Ihre Studie per E-Mail an: editors@skinonline.at